Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
DSCI's Cash to Debt is ranked higher than
91% of the 292 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.03 vs. DSCI: No Debt )
DSCI' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: No Debt

Equity to Asset 0.90
DSCI's Equity to Asset is ranked higher than
95% of the 290 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.58 vs. DSCI: 0.90 )
DSCI' s 10-Year Equity to Asset Range
Min: 0.46   Max: 0.9
Current: 0.9

0.46
0.9
Interest Coverage No Debt
DSCI's Interest Coverage is ranked higher than
96% of the 178 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.54 vs. DSCI: No Debt )
DSCI' s 10-Year Interest Coverage Range
Min: 0.23   Max: 9999.99
Current: No Debt

0.23
9999.99
F-Score: 5
Z-Score: 9.33
M-Score: -2.86
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -47.89
DSCI's Operating margin (%) is ranked higher than
52% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.64 vs. DSCI: -47.89 )
DSCI' s 10-Year Operating margin (%) Range
Min: -47.89   Max: 4.71
Current: -47.89

-47.89
4.71
Net-margin (%) -47.49
DSCI's Net-margin (%) is ranked higher than
53% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.36 vs. DSCI: -47.49 )
DSCI' s 10-Year Net-margin (%) Range
Min: -47.49   Max: 2.4
Current: -47.49

-47.49
2.4
ROE (%) -31.41
DSCI's ROE (%) is ranked higher than
55% of the 281 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.53 vs. DSCI: -31.41 )
DSCI' s 10-Year ROE (%) Range
Min: -71.88   Max: 6.13
Current: -31.41

-71.88
6.13
ROA (%) -28.73
DSCI's ROA (%) is ranked higher than
53% of the 294 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.84 vs. DSCI: -28.73 )
DSCI' s 10-Year ROA (%) Range
Min: -41.07   Max: 4.65
Current: -28.73

-41.07
4.65
ROC (Joel Greenblatt) (%) -192.89
DSCI's ROC (Joel Greenblatt) (%) is ranked higher than
51% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.54 vs. DSCI: -192.89 )
DSCI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -207.97   Max: 16.67
Current: -192.89

-207.97
16.67
Revenue Growth (3Y)(%) -12.20
DSCI's Revenue Growth (3Y)(%) is ranked higher than
55% of the 259 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.60 vs. DSCI: -12.20 )
DSCI' s 10-Year Revenue Growth (3Y)(%) Range
Min: -40.2   Max: 11.5
Current: -12.2

-40.2
11.5
EBITDA Growth (3Y)(%) 145.80
DSCI's EBITDA Growth (3Y)(%) is ranked higher than
99% of the 224 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.90 vs. DSCI: 145.80 )
DSCI' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -75.4   Max: 161.3
Current: 145.8

-75.4
161.3
EPS Growth (3Y)(%) 49.00
DSCI's EPS Growth (3Y)(%) is ranked higher than
95% of the 222 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.20 vs. DSCI: 49.00 )
DSCI' s 10-Year EPS Growth (3Y)(%) Range
Min: -29.7   Max: 122.4
Current: 49

-29.7
122.4
» DSCI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

DSCI Guru Trades in Q1 2014

Jim Simons 95,281 sh (New)
Chuck Royce 55,000 sh (unchged)
» More
Q2 2014

DSCI Guru Trades in Q2 2014

Chuck Royce 55,000 sh (unchged)
Jim Simons Sold Out
» More
Q3 2014

DSCI Guru Trades in Q3 2014

Chuck Royce 55,000 sh (unchged)
» More
Q4 2014

DSCI Guru Trades in Q4 2014

Jim Simons 15,623 sh (New)
Chuck Royce 162,100 sh (+194.73%)
» More
» Details

Insider Trades

Latest Guru Trades with DSCI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.80
DSCI's P/B is ranked higher than
84% of the 310 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.76 vs. DSCI: 1.80 )
DSCI' s 10-Year P/B Range
Min: 0.5   Max: 3.42
Current: 1.8

0.5
3.42
P/S 2.57
DSCI's P/S is ranked higher than
66% of the 310 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.96 vs. DSCI: 2.57 )
DSCI' s 10-Year P/S Range
Min: 0.21   Max: 3.26
Current: 2.57

0.21
3.26
EV-to-EBIT -3.80
DSCI's EV-to-EBIT is ranked higher than
59% of the 310 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.73 vs. DSCI: -3.80 )
DSCI' s 10-Year EV-to-EBIT Range
Min: -224.5   Max: 134.7
Current: -3.8

-224.5
134.7
Current Ratio 8.76
DSCI's Current Ratio is ranked higher than
95% of the 289 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.66 vs. DSCI: 8.76 )
DSCI' s 10-Year Current Ratio Range
Min: 1.54   Max: 8.76
Current: 8.76

1.54
8.76
Quick Ratio 7.61
DSCI's Quick Ratio is ranked higher than
95% of the 289 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.79 vs. DSCI: 7.61 )
DSCI' s 10-Year Quick Ratio Range
Min: 0.45   Max: 7.61
Current: 7.61

0.45
7.61
Days Inventory 109.52
DSCI's Days Inventory is ranked higher than
77% of the 310 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 122.29 vs. DSCI: 109.52 )
DSCI' s 10-Year Days Inventory Range
Min: 85.54   Max: 346.75
Current: 109.52

85.54
346.75
Days Sales Outstanding 38.17
DSCI's Days Sales Outstanding is ranked higher than
95% of the 310 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 69.21 vs. DSCI: 38.17 )
DSCI' s 10-Year Days Sales Outstanding Range
Min: 14.87   Max: 119.02
Current: 38.17

14.87
119.02

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.50
DSCI's Price/Net Cash is ranked higher than
97% of the 310 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.00 vs. DSCI: 2.50 )
DSCI' s 10-Year Price/Net Cash Range
Min: 5.22   Max: 17.74
Current: 2.5

5.22
17.74
Price/Net Current Asset Value 2.00
DSCI's Price/Net Current Asset Value is ranked higher than
95% of the 310 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.00 vs. DSCI: 2.00 )
DSCI' s 10-Year Price/Net Current Asset Value Range
Min: 0.79   Max: 9.91
Current: 2

0.79
9.91
Price/Tangible Book 2.20
DSCI's Price/Tangible Book is ranked higher than
86% of the 310 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.06 vs. DSCI: 2.20 )
DSCI' s 10-Year Price/Tangible Book Range
Min: 0.42   Max: 9.9
Current: 2.2

0.42
9.9
Price/Median PS Value 4.00
DSCI's Price/Median PS Value is ranked higher than
50% of the 310 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.33 vs. DSCI: 4.00 )
DSCI' s 10-Year Price/Median PS Value Range
Min: 0.14   Max: 5.39
Current: 4

0.14
5.39
Earnings Yield (Greenblatt) -26.70
DSCI's Earnings Yield (Greenblatt) is ranked lower than
53% of the 293 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.50 vs. DSCI: -26.70 )
DSCI' s 10-Year Earnings Yield (Greenblatt) Range
Min: -26.7   Max: 48.5
Current: -26.7

-26.7
48.5

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Derma Sciences Inc was incorporated on September 10, 1984. The Company is a tissue regeneration company engaged in three segments of the wound care marketplace: pharmaceutical wound care, advanced wound care and traditional wound care products. The Company has one drug candidate that initiated its Phase 3 study. The Company maintains manufacturing facilities in Toronto, Canada and Nantong, China and an established network of third party suppliers for its products. Its products are sold through distributors to health care providers such as wound care centers, extended care facilities, acute care facilities, home health care agencies and physicians' offices. Some of its products are sold through retail channels to care givers. The Company markets its products through direct sales representatives in the United States, Canada and the United Kingdom, and through independent distributors within other select international markets. In Pharmaceutical Wound Care, the DSC127 product is in clinical trial for the treatment of diabetic foot ulcers. The Phase 3 clinical trial for diabetic foot ulcers is expected to be completed by the end of 2015. In addition to the diabetic foot ulcer indication, the Company has begun preclinical testing for scar reduction. The product lines in Advanced Wound Care include MEDIHONEY, TCC-EZ, AMNIOEXCEL and AMNIOMATRIX, XTRASORB, BIOGUARD, and ALGICELL AG. The Traditional Wound Care line consists of gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages and other compression devices. It also manufactures and market adhesive bandages and related first aid products for the medical, industrial, private label and retail markets. It markets a line of wound closure strips, nasal tube fasteners and a variety of catheter fasteners to doctors, clinics, nursing homes, hospitals and other institutions.
» More Articles for DSCI

Headlines

Articles On GuruFocus.com
Derma Sciences Inc. Reports Operating Results (10-Q) Nov 12 2010 
Derma Sciences Inc. Reports Operating Results (10-Q) May 12 2010 

More From Other Websites
Broadfin Buffs Up on Zogenix, Inc. (ZGNX) and Derma Sciences Inc (DSCI) Mar 19 2015
DERMA SCIENCES, INC. Financials Mar 18 2015
Derma Sciences Inc Earnings Call scheduled for 11:00 am ET today Mar 12 2015
Derma Sciences reports 4Q loss Mar 12 2015
Derma Sciences reports 4Q loss Mar 12 2015
Derma Sciences Reports Fourth Quarter and Year Ended Financial Results Mar 12 2015
Derma Sciences Reports Fourth Quarter and Year Ended Financial Results Mar 12 2015
Q4 2014 Derma Sciences Inc Earnings Release - Time Not Supplied Mar 12 2015
DERMA SCIENCES, INC. Files SEC form 10-K, Annual Report Mar 11 2015
Derma Sciences Names Pharmaceutical Development Leader John Caminis, M.D. as Chief Medical Officer Mar 09 2015
Derma Sciences Names Pharmaceutical Development Leader John Caminis, M.D. as Chief Medical Officer Mar 09 2015
Derma Sciences to Hold Fourth Quarter Financial Results Conference Call on March 12th Mar 04 2015
Derma Sciences to Hold Fourth Quarter Financial Results Conference Call on March 12th Mar 04 2015
Derma Sciences to Present at the 27th Annual Roth Conference Mar 04 2015
Derma Sciences to Present at the 27th Annual Roth Conference Mar 04 2015
Connecture Inc (CNXR), Hyperion Therapeutics Inc (HPTX): Top 5 Healthcare Picks of Great Point... Mar 02 2015
Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement Jan 22 2015
Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement Jan 22 2015
Derma Sciences Introduces 2015 Financial Guidance and Provides 2014 Preliminary Net Sales Jan 08 2015
Derma Sciences Introduces 2015 Financial Guidance and Provides 2014 Preliminary Net Sales Jan 08 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK